Next-Gen CDK4-Selective Inhibitor PF-07220060 shines in first-in-human Phase I/IIa study, unveiling impressive results for advanced solid tumors enriched with HR+ HER2- mBC patients who experienced prior CDK4/6 Inhibitor and endocrine therapy progression